Allergy Therapeutics plc (LON:AGY – Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 9.01 and traded as low as GBX 5.25. Allergy Therapeutics shares last traded at GBX 5.29, with a volume of 19,451 shares traded.
Allergy Therapeutics Stock Up 2.7%
The company has a market capitalization of £341.32 million, a P/E ratio of -5.56, a price-to-earnings-growth ratio of -30.70 and a beta of 0.87. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The company has a 50-day moving average of GBX 6.38 and a two-hundred day moving average of GBX 8.97.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
